Increased Gross Business Awards
Gross business awards increased 11% on a sequential basis over quarter 1, with notable wins from several biotech customers and large pharma partnerships.
Revenue Performance Exceeds Expectations
Revenue in quarter 2 was $2.017 billion, representing a year-on-year decrease of 4.8%, but up approximately 1% sequentially on quarter 1 2025, with higher pass-through revenue assisting performance.
Improvement in Gross Margin and Cost Management
Gross margin improved over quarter 1 to 28.3%, and SG&A costs reduced by $9 million year-over-year, demonstrating efficient global operations.
Positive Developments in Key Operational Areas
Customer and site satisfaction scores improved due to accelerated site activation, patient recruitment, and trial completion. Investments in obesity and related metabolic diseases are progressing well.
Significant Share Repurchases
In quarter 2, $250 million in shares were repurchased, and a new share repurchase authorization for up to $1 billion was approved.